Results from the randomized VOLFI trial (AIO KRK-0109) showed that the increased toxicity with FOLFOXIRI+/- panitumumab treatment did not translate into impaired quality of life. (Poster 580P, M. Geissler et al.).
A retrospective analysis of PRIME study (FOLFOX +/- Panitumumab as 1L in mCRC) assessed whether Köhne category predicts Early Tumor Shrinkage and Depth of Response and whether survival outcomes of patients achieving ETS or high DpR differ according to baseline Köhne category.
Panitumumab posters at ESMO